Status:
COMPLETED
A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Neuralgia
Neuralgia, Postherpetic
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to assess the reproducibility and the effect of gabapentin on quantitative sensory testing assessments in neuropathic pain subjects.
Eligibility Criteria
Inclusion
- Neuropathic pain of peripheral origin as a consequence of either post-herpetic neuralgia or post-traumatic neuropathic pain
- Well-defined skin area of mechanical allodynia to punctate (von Frey filament) stimuli
- Pain intensity score of ≥ 4/10 for von Frey filament-evoked allodynia at the skin area
Exclusion
- Patients who have undergone neurolytic or neurosurgical therapy, including skin excisions, for neuropathic pain
- Patients who have trigeminal neuralgia, central pain, chronic radiculopathy, or peripheral neuropathy of non-mechanical or unknown origin
- Patients with any other co-existing pain which cannot be differentiated from the neuropathic pain of peripheral origin
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00674687
Start Date
July 1 2004
End Date
June 1 2006
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Liverpool, United Kingdom, L9 7AL